Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 199Magnetic Resonance Spectroscopy 150Biopsy 121pembrolizumab 94Carboplatin 85Cisplatin 77Nivolumab 74Cyclophosphamide 70Paclitaxel 65Gemcitabine 53Radiotherapy 49Bevacizumab 45durvalumab 41Dexamethasone 39Fluorouracil 35Doxorubicin 35Capecitabine 35venetoclax 34olaparib 33atezolizumab 33Pemetrexed 33Injections 32Rituximab 31Oxaliplatin 31Radiation 29Prednisone 29Etoposide 29fludarabine 28Lenalidomide 28cemiplimab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × methoxyamine × 30 days × Clear all
NCT05198830 2026-05-27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
42 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡